Keywords: Polyendocrine Metabolic Ovarian Syndrome (PMOS), Polycystic Ovary Syndrome (PCOS), Insulin Resistance, Hyperandrogenism, Metabolic Syndrome, Type 2 Diabetes, Cardiovascular Risk, Longevity, Disease Prevention

Introduction

For decades, millions of women were told they had a condition defined by cysts on their ovaries. Many of those women never had a single cyst. They had irregular periods, excess hair growth, weight they struggled to lose, skin that broke out without warning, and a persistent exhaustion that no amount of sleep could fix. They were shuffled between gynecologists, dermatologists, and endocrinologists, each treating one piece of a puzzle that no one seemed to see whole. They were told to lose weight, take the pill, and come back if they wanted to get pregnant. Rarely were they told that their body was, at its core, fighting an insulin problem, a hormone imbalance, and a metabolic fire that, left unaddressed, would substantially raise their risk of type 2 diabetes, cardiovascular disease, and a shortened health span.

That era is ending. On 12 May 2026, a landmark global consensus published in The Lancet officially renamed polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome, or PMOS. The renaming was not cosmetic. It emerged from over a decade of scientific deliberation, input from more than 22,000 patients and healthcare professionals across 195 countries, and collaboration across 56 leading academic and clinical organizations. The new name reflects a fundamental shift in how medicine understands this condition: not as a disorder of ovarian morphology, but as a systemic metabolic and endocrine disease that happens to express itself most visibly in the reproductive system [1,2].

The timing of this change matters. We are living through a global epidemic of metabolic disease, in which insulin resistance, type 2 diabetes, cardiovascular dysfunction, and non-alcoholic fatty liver disease are collectively reshaping human health span. Women with PMOS sit at the intersection of all of these risk factors, often from a young age, often without realizing it. Yet because their primary complaints involve periods and fertility, they have historically received care oriented around reproduction rather than metabolism. The result has been missed opportunities for early intervention, years of fragmented care, and a preventable accumulation of metabolic damage.

This article is written for women living with PMOS, for those who suspect they may have it, and for anyone who cares about women’s long-term health. It draws on current evidence to explain what PMOS is at the level of biology, what it does to the body beyond the ovaries, how to recognize and diagnose it, and how to treat it in a way that addresses its roots rather than just its branches. Above all, it argues that PMOS is not a sentence, but a signal: an early warning from the body’s metabolic systems that, when heeded and acted upon, can be the starting point for a lifetime of better health.

A Name Born from Misconception: The History of PCOS

The condition now known as PMOS was first described in 1935 by two American gynecologists, Irving Stein and Michael Leventhal, who observed that a group of young women with menstrual irregularities and infertility had enlarged ovaries studded with small fluid-filled structures. They called it the Stein-Leventhal syndrome, and the “polycystic” descriptor was born from what they saw under the surgical knife. Almost a century later, that observation still lives in the acronym millions of women are given at diagnosis [3].

The problem is that what Stein and Leventhal saw were not pathological cysts in any conventional sense. They were, in fact, a collection of immature follicles, small egg-containing sacs that had failed to fully develop and release an egg. This follicular arrest is a consequence of the hormonal imbalance at the heart of PMOS, not the cause of the condition itself. Many women with PMOS do not have polycystic ovarian morphology on ultrasound at all; conversely, many women without PMOS do. Research has consistently shown that the “polycystic” appearance on ultrasound neither defines the condition nor reliably predicts its severity [1,4].

The consequences of this misnaming have been significant. For patients, hearing that they have “cysts” on their ovaries triggers fear of cancer, surgery, and permanent damage, none of which are features of PMOS. It directs attention toward the ovaries as the site of the disease, when the true origin lies in systemic metabolic and hormonal dysfunction. It obscures the condition’s relationship to insulin resistance, androgen excess, and long-term cardiometabolic risk, leaving many women and their doctors focused on managing symptoms such as irregular periods or excess hair growth rather than addressing the underlying metabolic disturbance.

For clinicians, the old name contributed to what researchers have called “fragmented care”: the condition tended to live in gynecology when a patient was trying to conceive, in dermatology when she was dealing with acne or hirsutism, and in no specialty at all when it came to monitoring her lifetime risk of diabetes and cardiovascular disease. Studies show that up to 70% of women with PMOS remain undiagnosed, and those who are diagnosed often wait years before receiving an accurate explanation of what is happening in their bodies [1,2].

The campaign to rename the condition has been building for more than a decade. The final consensus paper, published in The Lancet and presented at the European Congress of Endocrinology in Prague, was the result of collaboration across 56 organizations and iterative surveys gathering responses from over 14,300 patients and multidisciplinary health professionals worldwide. Eighty-six percent of patients and 71% of clinicians supported adopting a new name. The winning term, polyendocrine metabolic ovarian syndrome, was chosen because it accurately describes what the science has shown: a condition driven by multiple interacting hormonal disturbances, rooted in metabolic dysfunction, and centered on the ovaries as a target organ rather than the source [1,2].

The International Classification of Diseases is expected to be updated to reflect the new name by 2028, with guidelines across 195 countries being revised over the next three years. The linguistic change is already underway. The scientific paradigm shift it represents has, in many ways, been building for decades [2].

What PMOS Really Means: Decoding the New Name

The name polyendocrine metabolic ovarian syndrome is longer than its predecessor, but every word carries meaning. Understanding the name is the first step toward understanding the condition.

Poly means many. It signals immediately that this condition involves more than one system, more than one hormone, and more than one mechanism. PMOS is not caused by a single broken gene or a single malfunctioning organ. It arises from the interaction of multiple disrupted pathways.

Endocrine refers to the body’s hormonal signaling system. The endocrine system includes the pancreas (which produces insulin), the ovaries (which produce sex hormones), the adrenal glands (which produce androgens and stress hormones), the hypothalamus and pituitary gland (which regulate the entire hormonal cascade from the brain), and more. In PMOS, several of these systems are dysregulated simultaneously and interact with each other in ways that perpetuate the disorder. This is why PMOS requires a systemic view, not just a gynecological one.

Metabolic is perhaps the most important word in the new name, and the one most absent from the old one. Metabolism refers to all the chemical processes the body uses to convert food into energy, regulate blood sugar, manage fat storage, and maintain the balance of molecules that keep every cell functioning. In PMOS, the metabolic machinery is compromised at a fundamental level. Insulin resistance, the core metabolic defect, precedes and drives almost every other feature of the condition. This word places PMOS firmly in the category of metabolic disease, alongside type 2 diabetes and metabolic syndrome, rather than in the narrower category of reproductive dysfunction.

Ovarian confirms that the ovaries remain central to the condition’s expression. They are not the source of the disease, but they are the organ most visibly affected by the underlying hormonal and metabolic disturbance. Ovulatory dysfunction and the hormonal environment within the ovary are what produce the menstrual irregularities and fertility challenges that often bring women to medical attention in the first place.

Syndrome acknowledges that PMOS is not a single, uniform disease but a collection of features that cluster together. Different women experience it differently. Some have primarily metabolic symptoms; others have primarily reproductive or dermatological ones. The syndrome label validates this heterogeneity while uniting diverse presentations under a single biological framework.

Together, the name PMOS tells a story: a condition in which the body’s hormonal systems, primarily but not exclusively the insulin-androgen axis, are dysregulated in interconnected ways that express themselves through the ovaries but affect the entire body. Treating the name seriously means treating the whole person, not just the presenting symptom.

The Metabolic Engine: How Insulin Resistance Drives PMOS

At the heart of PMOS is a problem with insulin. To understand why, it helps to start with what insulin is supposed to do.

Insulin is a hormone produced by the pancreas in response to rising blood sugar after a meal. Its job is to act as a key, unlocking cells throughout the body so that glucose can enter and be used for energy. When insulin signalling works normally, blood sugar rises after eating, insulin is released, cells open up to absorb glucose, and blood sugar returns to normal. It is an elegant, self-regulating system.

In insulin resistance, however, the cells stop responding to insulin’s signal. They become, in effect, resistant to the key. The pancreas compensates by producing more and more insulin, trying to force the doors open. This state, known as hyperinsulinemia, or abnormally high circulating insulin, is the central metabolic driver of PMOS [4,5].

Insulin resistance affects approximately 35 to 80% of women with PMOS, depending on the population studied and how it is measured. Critically, it is not confined to women who are overweight. Even lean women with PMOS demonstrate insulin resistance, indicating that this is an intrinsic biological feature of the condition, not simply a consequence of excess body fat. This point is poorly understood by many clinicians and is one of the most common reasons that lean women with PMOS are dismissed or misdiagnosed [4,5,6].

What does hyperinsulinemia do to the ovaries? This is where the biology becomes particularly important. While most tissues become resistant to insulin’s metabolic effects (its ability to promote glucose uptake), the ovaries retain their sensitivity to insulin’s other actions. This phenomenon, called selective insulin resistance, means that high insulin levels continue to directly stimulate the ovarian cells that produce androgens, particularly the theca cells. Insulin works in concert with luteinizing hormone (LH) from the pituitary gland to amplify androgen production. The result is hyperandrogenism: elevated levels of testosterone and related hormones that cause the hallmark symptoms of excess facial and body hair, acne, scalp hair thinning, and disrupted ovulation [7,8,9].

At the same time, high insulin suppresses the liver’s production of sex hormone-binding globulin (SHBG), a protein that normally binds to testosterone in the bloodstream and renders it inactive. When SHBG falls, more free, biologically active testosterone circulates through the body, intensifying androgenic symptoms even when total testosterone levels appear only modestly elevated on standard lab tests [8].

This creates a self-reinforcing loop. Insulin resistance leads to hyperinsulinemia. Hyperinsulinemia stimulates ovarian androgen production. Androgens, particularly in adipose tissue, further impair insulin signalling, worsening insulin resistance. At the same time, anovulation and the absence of progesterone from the normal monthly cycle deprive the body of a hormone that, among other functions, improves insulin sensitivity. The result is a biological feedback loop in which each component drives the others, making PMOS self-perpetuating without intervention [4,5,8].

The metabolic consequences extend far beyond the ovaries. Women with PMOS have a two- to four-fold increased lifetime risk of developing type 2 diabetes compared to women without the condition, after accounting for body weight. Up to one-third of women with PMOS have impaired glucose tolerance, and up to 10% have frank type 2 diabetes, often by early to mid-adulthood. Rates of metabolic syndrome, a cluster of central obesity, elevated triglycerides, reduced HDL cholesterol, elevated blood pressure, and impaired glucose regulation, are substantially higher in PMOS than in the general female population [4,6,10,11].

Understanding insulin resistance as the metabolic engine of PMOS transforms how the condition should be approached clinically. It is not enough to manage menstrual irregularities or cosmetic symptoms with hormonal contraceptives and move on. The metabolic root requires metabolic treatment.

The Polyendocrine Dimension: When Multiple Hormones Go Awry

The “poly” and “endocrine” in PMOS are not decorative. The condition involves a cascade of interacting hormonal disruptions that span the brain, the adrenal glands, the pancreas, and the ovaries. Understanding this complexity helps explain why PMOS presents so differently in different women and why simple, single-target treatments so often fall short.

At the top of the hormonal hierarchy is the hypothalamus, a small brain region that acts as the master regulator of reproductive and metabolic hormones. In PMOS, the hypothalamus appears to be caught in a state of hyperactivity. Neurons in a region called the arcuate nucleus, specifically a population known as KNDy neurons (named for the three neurotransmitters they release: kisspeptin, neurokinin B, and dynorphin), fire more frequently than normal, driving an elevated pulse frequency of gonadotropin-releasing hormone (GnRH) release. This has a cascade effect: elevated GnRH pulses stimulate the pituitary gland to produce more luteinizing hormone (LH) relative to follicle-stimulating hormone (FSH). The resulting imbalance, a high LH-to-FSH ratio, promotes androgen production from theca cells while simultaneously impairing the maturation of follicles in the ovary, contributing to the follicular arrest that gives rise to the characteristic ultrasound appearance [3,9].

Androgens themselves are a key polyendocrine component. While the ovaries are a major source of excess androgens in PMOS, the adrenal glands contribute as well. Elevated dehydroepiandrosterone sulfate (DHEAS) and androstenedione, adrenal androgens, are found in a substantial proportion of women with PMOS, suggesting that adrenal over-reactivity to stress hormones is also part of the picture. This adrenal component may explain why stress, poor sleep, and cortisol dysregulation appear to worsen PMOS symptoms in many women [5,8].

The gut microbiome adds another layer of complexity. Research in recent years has shown that the composition of gut bacteria influences insulin sensitivity, systemic inflammation, and sex hormone metabolism. Women with PMOS have been found to have altered gut microbiome profiles compared to those without the condition, including reduced microbial diversity and shifts in the balance of bacterial species that produce short-chain fatty acids, which are important regulators of metabolic health. An imbalanced gut microbiome increases intestinal permeability, allowing bacterial fragments called lipopolysaccharides to leak into the bloodstream. These molecules trigger a chronic, low-grade inflammatory state that worsens insulin resistance, further fueling the PMOS cycle [3].

Adipose tissue, particularly the visceral fat stored around the abdominal organs, is itself an active endocrine organ in PMOS. Adipose tissue converts androgens into other sex hormones and releases signaling molecules called adipokines that regulate insulin sensitivity, appetite, and inflammation. In women with PMOS, adiponectin, an anti-inflammatory adipokine that improves insulin sensitivity, is often low, while pro-inflammatory cytokines are elevated. This adipose-androgen feedback loop amplifies the metabolic and androgenic features of the condition, particularly in women with central obesity [12,13].

The polyendocrine nature of PMOS means that there is no single hormonal villain to target. The condition is the product of a system, not a single defect, and that system-level perspective is what the new name encodes.

The Full-Body Impact: From Ovaries to Heart, Liver, and Brain

The name polyendocrine metabolic ovarian syndrome centers the ovaries, but the body does not read medical diagnoses. PMOS affects virtually every organ system, and the consequences accumulate over a lifetime if the underlying metabolic disturbance goes unaddressed.

Cardiovascular System

Women with PMOS have a substantially elevated risk of cardiovascular disease. A comprehensive 2024 meta-analysis found approximately two-fold higher risks of coronary artery disease, heart attack, and stroke in women with PMOS compared to those without the condition. Evidence from long-term prospective population studies confirms that this risk elevation persists regardless of whether the condition is diagnosed by strict or broad criteria, and appears to accelerate cardiovascular aging [12,13].

Subclinical signs of vascular damage are already detectable in young women with PMOS, decades before clinical cardiovascular events typically occur. Increased carotid intima-media thickness, a marker of early atherosclerosis, has been documented in PMOS cohorts. Endothelial dysfunction, the impaired ability of blood vessel walls to dilate properly, is measurable in young PMOS patients and correlates directly with insulin resistance and low adiponectin levels. These changes reflect accelerated vascular aging driven by the chronic metabolic and inflammatory milieu of PMOS [14].

The cardiovascular risk profile in PMOS includes atherogenic dyslipidemia (elevated triglycerides, low HDL cholesterol, elevated LDL cholesterol), hypertension, central adiposity, and chronic low-grade inflammation. These features cluster together and act synergistically, creating a cardiometabolic burden that major professional organizations, including the American Heart Association, now recognize as warranting routine cardiovascular risk assessment in women with PMOS [15].

Liver

Non-alcoholic fatty liver disease, now more precisely called metabolic dysfunction-associated steatotic liver disease (MASLD), is significantly more prevalent in women with PMOS than in the general population. The condition develops when excess fat accumulates in liver cells, driven by insulin resistance and the metabolic processes it disrupts. Left untreated, MASLD can progress to non-alcoholic steatohepatitis, fibrosis, and cirrhosis. Large UK-based cohort studies have confirmed that women with PMOS face a significantly elevated risk of MASLD, independent of obesity. Liver health is therefore an essential but frequently overlooked component of PMOS management [16,17].

Mental Health

The psychological burden of PMOS is substantial and frequently underestimated. Rates of depression and anxiety are significantly elevated in women with PMOS compared to the general population, driven by a combination of biological factors (including the direct neurological effects of androgen excess and insulin resistance), the psychosocial impact of symptoms such as hirsutism and acne on self-image and identity, and the frustration of living with a poorly understood, frequently dismissed condition. Disordered eating is also more common in PMOS, and eating disorders can both worsen and be worsened by the metabolic features of the condition. Mental health must be assessed and addressed as an integral component of PMOS care, not a secondary concern.

Sleep

Obstructive sleep apnea is significantly more prevalent in women with PMOS than in weight-matched controls, likely related to both central adiposity and the direct effects of androgen excess on upper airway muscle tone. Sleep apnea, in turn, worsens insulin resistance and metabolic dysfunction, creating another bidirectional feedback loop. Women with PMOS who report excessive fatigue, loud snoring, or unrefreshing sleep should be evaluated for sleep-disordered breathing.

Skin and Hair

Hyperandrogenism produces the most visible manifestations of PMOS: hirsutism (excess facial and body hair, typically in a male distribution), acne, and androgenic alopecia (scalp hair thinning). These symptoms cause profound distress and are often the reason women first seek medical attention. While they can be managed with cosmetic and pharmaceutical interventions, the most durable improvements come from addressing the underlying metabolic and hormonal drivers.

The full-body impact of PMOS underscores why it requires an integrated, multidisciplinary approach, and why treating it as a “gynecological problem” profoundly underserves the women living with it.

Who Has PMOS? Understanding the Spectrum

One of the most important things to understand about PMOS is that it does not look the same in every woman. The condition is a spectrum, and the biological diversity within that spectrum has significant implications for both diagnosis and management.

PMOS is formally diagnosed using criteria that require the presence of at least two of three features: irregular or absent ovulation, clinical or biochemical hyperandrogenism (elevated androgen levels or symptoms such as hirsutism), and polycystic ovarian morphology on ultrasound. Using these criteria, four distinct phenotypes have been described [18,19]:

Phenotype A, considered the “classic” presentation, involves all three features: anovulation, hyperandrogenism, and polycystic ovarian morphology. This phenotype carries the highest metabolic risk, with the greatest prevalence of insulin resistance, dyslipidemia, and metabolic syndrome [18,19].
Phenotype B involves anovulation and hyperandrogenism without polycystic ovarian morphology on ultrasound. It is metabolically similar to Phenotype A, with comparable insulin resistance and cardiometabolic risk [18].
Phenotype C involves hyperandrogenism and polycystic ovarian morphology but with preserved ovulation. Metabolic risk is intermediate, elevated compared to women without PMOS but generally less severe than in Phenotypes A and B [18,19].
Phenotype D involves anovulation and polycystic ovarian morphology without hyperandrogenism. This is the most metabolically “mild” phenotype, though it still confers elevated risk compared to women without PMOS [18].

A critical point for both clinicians and patients is that insulin resistance and metabolic risk are not restricted to the classic, hyperandrogenic phenotypes. Even women with Phenotype D, who lack overt hyperandrogenism, can exhibit clinically significant insulin resistance. This means that all women with a PMOS diagnosis, regardless of which features are present and regardless of body weight, should receive metabolic evaluation [19,20].

Lean women with PMOS deserve special mention. Because the condition is so strongly associated with obesity in the public and clinical imagination, lean women are frequently dismissed or told their PMOS is “mild” without proper metabolic investigation. Research consistently shows that lean PMOS is a real and clinically significant entity, with insulin resistance, androgen excess, and elevated long-term risk of metabolic complications in many cases. Body weight modifies but does not eliminate PMOS-related metabolic risk [6].

The Hidden Burden: Delays in Diagnosis and Fragmented Care

Despite affecting between one in eight and one in ten women of reproductive age, PMOS remains startlingly underdiagnosed. Surveys estimate that up to 70% of women with PMOS have never received a diagnosis. Among those who are eventually diagnosed, the journey to get there is often measured in years, during which the underlying metabolic disturbance quietly progresses [1].

The reasons for diagnostic delay are multiple and interlocking. First, the condition’s symptoms are diverse and can be attributed to many other causes. Irregular periods may be dismissed as “just stress.” Acne is treated topically without investigation. Weight gain is attributed to lifestyle without exploring its hormonal basis. Fatigue is explained away. Women’s reports of their symptoms are often minimized, and the connections between disparate complaints are rarely drawn.

Second, because PMOS was historically framed as a reproductive condition, it lived primarily in gynecology. A woman who was not trying to conceive, or who had been offered the oral contraceptive pill to regulate her periods and considered the matter resolved, would have no further investigation of her underlying metabolic status. The oral contraceptive pill, while effective at managing menstrual irregularity and androgen-related symptoms, does not treat insulin resistance, does not reduce long-term cardiovascular risk, and can in some cases worsen lipid profiles and glucose tolerance, particularly at higher progestogen doses [3].

Third, the fragmentation of medical specialties means that no single clinician has historically “owned” PMOS across its full clinical profile. The gynecologist manages fertility. The dermatologist treats skin. The dietitian advises on weight. The endocrinologist may see only the most severely affected cases. No one monitors the annual oral glucose tolerance test that current guidelines recommend. No one checks the lipid profile. No one calculates cardiovascular risk [1,2].

The renaming of the condition to PMOS, and the explicit naming of metabolic features within the diagnosis itself, is designed in part to address this fragmentation. When a condition is called “metabolic” in its name, it becomes harder to justify managing it only with hormonal contraception and reproductive advice. It signals to clinicians across specialties that this patient’s care plan should include metabolic screening, lifestyle intervention, and long-term cardiometabolic monitoring.

For patients, the name change carries a different but equally important message: you deserve to have your full diagnosis explained to you. You deserve to understand why your body does what it does. You deserve a clinical team that looks beyond your ovaries and sees your metabolic health as the central project of your long-term care.

Treating the Root: A Metabolic-Frist Approach to PMOS

The shift from PCOS to PMOS in nomenclature is meaningless unless it is accompanied by a shift in how the condition is treated. A metabolic-first approach does not abandon reproductive and symptomatic management; it builds a more durable foundation beneath it.

Lifestyle as First-Line Medicine

The most powerful tool available for managing PMOS is also the one most frequently undervalued: lifestyle modification. Randomized controlled trials and systematic reviews consistently show that structured lifestyle programs, combining dietary change with regular physical activity, improve insulin sensitivity, reduce androgen levels, restore ovulatory cycles, improve lipid profiles, lower blood pressure, and reduce symptoms of depression and anxiety in women with PMOS [21,22].

Dietary approaches with the strongest evidence emphasize reducing refined carbohydrates and added sugars, prioritizing whole foods with a low glycemic index, increasing dietary fiber, and adopting anti-inflammatory patterns such as the Mediterranean diet. These strategies directly target hyperinsulinemia by reducing postprandial glucose spikes and improving the body’s insulin response over time. They also reduce systemic inflammation and support a healthier gut microbiome. Caloric restriction alone, without attention to dietary quality, is substantially less effective than dietary approaches designed specifically to improve insulin sensitivity [21].

Physical activity acts through complementary mechanisms. Aerobic exercise improves insulin sensitivity in skeletal muscle, the body’s largest glucose disposal site. Resistance training builds muscle mass, which is itself metabolically protective and increases the body’s capacity to absorb glucose without insulin. Combined programs that include both aerobic and resistance components produce the greatest improvements in insulin resistance, body composition, and hormonal parameters in PMOS. Even modest increases in physical activity are beneficial: the goal is not extreme exercise but consistent, sustainable movement [22].

Critically, the benefits of lifestyle modification in PMOS are not contingent on achieving significant weight loss. Multiple studies show that metabolic and hormonal improvements occur in women with PMOS following lifestyle intervention independent of changes in body weight. This finding is important for lean and normal-weight women with PMOS, who may have been told there is little they can do because weight loss does not apply to their situation.

Metformin: The Insulin Sensitizer

Metformin, a medication originally developed for type 2 diabetes, is the most widely used pharmacological agent in PMOS. Its primary mechanism of action is to reduce hepatic glucose production and improve insulin sensitivity in peripheral tissues. In women with PMOS, metformin treatment has been shown to lower fasting insulin levels, improve glucose tolerance, reduce androgen concentrations, restore menstrual regularity, and modestly improve fertility outcomes. It has also been associated with favorable trends in lipid profiles and markers of subclinical vascular disease in some studies, including reductions in carotid intima-media thickness [9,22,23].

Current guidelines position metformin as a first-line pharmacological option, particularly for women with impaired glucose tolerance, type 2 diabetes, or prominent features of insulin resistance, and as an adjunct to lifestyle therapy rather than a replacement for it. Metformin is generally well tolerated, though gastrointestinal side effects, most commonly nausea and diarrhea, are common when starting treatment; these are minimized by beginning at a low dose and taking the medication with food [3,9].

GLP-1 Receptor Agonists: A Promising New Frontier

The emergence of glucagon-like peptide-1 (GLP-1) receptor agonists, medications such as semaglutide and liraglutide, as transformative treatments for obesity and type 2 diabetes has generated significant interest in their application to PMOS. GLP-1 receptor agonists work by enhancing insulin secretion in response to food, suppressing glucagon (a hormone that raises blood sugar), slowing gastric emptying, and reducing appetite. They produce substantial and sustained reductions in body weight and improve insulin sensitivity.

Early clinical evidence in women with PMOS is encouraging. GLP-1 receptor agonists appear to reduce hyperinsulinemia and androgen levels, improve ovulatory function, and produce favorable effects on lipid profiles and blood pressure. Some clinicians are already incorporating them into PMOS management for women with obesity and significant insulin resistance. Their role as a first-line agent, or as combination therapy with metformin, is an area of active clinical investigation. What is clear is that their mechanism of action, directly disrupting the insulin-theca cell androgen loop, is mechanistically aligned with the core pathophysiology of PMOS [3].

Hormonal Therapies: Managing Symptoms, Not the Root

Combined oral contraceptives (COCs) remain widely used in PMOS for their ability to regulate menstrual cycles, reduce androgen levels, and manage symptoms such as acne and hirsutism. Anti-androgen medications such as spironolactone offer additional benefit for androgen-driven symptoms. These interventions have an important role in managing the day-to-day impact of PMOS and improving quality of life, but they should be understood as symptomatic management rather than metabolic treatment. They do not address insulin resistance, do not reduce the long-term risks of type 2 diabetes or cardiovascular disease, and their effects on symptoms reverse when treatment is stopped. For women whose primary goal is metabolic health and prevention, hormonal therapies alone are insufficient [3,9].

Metabolic Monitoring: The Annual Review

All women with PMOS should receive regular metabolic monitoring as a standard of care. Current international evidence-based guidelines recommend an oral glucose tolerance test at the time of diagnosis, with repeat testing at least every one to three years depending on baseline risk. Fasting lipid profiles should be assessed at diagnosis and monitored regularly. Blood pressure, waist circumference, and body composition should be tracked over time. Women with PMOS who have experienced gestational diabetes are at particularly high risk of persistent glucose impairment and should receive intensive postpartum surveillance. Regular monitoring transforms PMOS from an acute diagnosis into a chronic condition with proactive, ongoing management [9,10,24].

PMOS Through a Longevity and Prevention Lens

Longevity medicine asks a simple but profound question: what can we do early, when the body is still resilient and the risks are still modifiable, to compress disease and extend health span? PMOS, understood through this lens, is one of the most important conditions in women’s preventive medicine.

Consider the timeline. A young woman is diagnosed with PMOS in her early twenties. She has insulin resistance, mildly elevated testosterone, irregular cycles, and an early metabolic syndrome. Her absolute risk of a heart attack today is almost zero. But her ovaries, blood vessels, liver, and metabolic machinery are already operating in a hormonal environment that, over decades, will accelerate aging. Without intervention, her risk of type 2 diabetes is two to four times higher than her peers over her lifetime. Her risk of cardiovascular disease is approximately doubled. Her liver is already accumulating metabolic stress that could progress to steatohepatitis if ignored [11,12,13,16,17].

Now consider the intervention. If that same young woman receives a diagnosis grounded in the metabolic reality of PMOS and is supported with appropriate lifestyle guidance, metabolic monitoring, and pharmacological support where needed, each of these trajectories becomes modifiable. Studies in women with PMOS and prediabetes, as well as in broader high-risk populations, show that structured lifestyle intervention can reduce the progression to type 2 diabetes by more than 50%. Improving insulin sensitivity in the third decade of life reduces the hormonal milieu that drives androgen excess, potentially improving both reproductive outcomes and long-term cardiometabolic health simultaneously [11].

From a longevity perspective, PMOS is also a window into family health. First-degree relatives of women with PMOS, including sisters, mothers, and potentially fathers and brothers through shared metabolic genetics, have elevated rates of insulin resistance, type 2 diabetes, and cardiovascular risk factors. A PMOS diagnosis in one family member can therefore trigger metabolic risk assessment across the family unit, multiplying the preventive impact of a single clinical encounter [3,4].

The economic argument for metabolic-first PMOS care is also compelling. The long-term costs of type 2 diabetes, cardiovascular disease, and their complications are among the largest drivers of healthcare expenditure globally. Women with PMOS, a group that is large (representing more than 170 million people worldwide), young, and carrying identifiable metabolic risk, represent an extraordinary opportunity for cost-effective prevention. Investing in their metabolic health in their twenties and thirties is substantially less expensive than managing myocardial infarctions, heart failure, diabetic nephropathy, and stroke in their fifties and sixties.

PMOS does not end at menopause. Although the reproductive features of the condition naturally resolve as ovarian function declines, the metabolic disturbances persist. Post-menopausal women with a history of PMOS continue to carry elevated cardiometabolic risk and require ongoing monitoring and management. The life course perspective embedded in the longevity medicine framework recognizes PMOS not as a reproductive phase condition but as a lifelong metabolic phenotype that requires lifelong attention.

For women living with PMOS, this perspective is both sobering and empowering. It means that the diagnosis matters, that the metabolic features are real and important, and that action taken now has a meaningful impact on the decades to come. It means that a PMOS diagnosis is not a life sentence but a life signal, one of the clearest early metabolic signals a woman’s body can give.

Conclusion

The renaming of polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome is one of the most significant developments in women’s metabolic health in decades. It is not a bureaucratic change. It is a scientific statement, ratified by tens of thousands of patients and hundreds of expert clinicians, that this condition has been misunderstood, mislabeled, and mismanaged for nearly a century, and that the time to correct that is now.

PMOS is, at its core, a metabolic disease. Insulin resistance and hyperinsulinemia are its engine. Androgen excess, neuroendocrine dysregulation, anovulation, and the full constellation of reproductive symptoms are its expression. The heart, liver, brain, skin, gut, and blood vessels are all involved. No single specialty owns this condition, and no single intervention cures it. Managing it well requires a systems-level view of the body and a life course view of health.

For women living with PMOS, the most important message is this: your diagnosis is not about your ovaries. It is about your metabolism. Understanding that shifts the entire framework of self-care, from focusing on periods and weight to understanding blood sugar, hormonal balance, inflammation, and the long-term health of the cardiovascular and metabolic systems. It opens the door to interventions, dietary, physical, pharmacological, and behavioral, that address the actual biology of the condition rather than its surface manifestations.

For clinicians, the new name is a call to action. Metabolic screening, lifestyle counselling, insulin sensitizing therapy, and cardiovascular risk assessment belong in every PMOS management plan, regardless of the patient’s weight, age, or reproductive goals. The woman in front of you today with irregular cycles and elevated testosterone is carrying a cardiometabolic risk profile that will accumulate over decades. The window to intervene, early, when the body is still resilient and the risks are still modifiable, is open. The metabolic lens is the right one through which to look.

PMOS is a condition at the crossroads of reproduction, metabolism, and longevity. Seeing it clearly, naming it accurately, and treating it comprehensively is one of the most powerful acts of preventive medicine available in women’s health today.

Reference

1. Teede HJ, Tay CT, Mousa A, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026; pii: S0140-6736(26)00717-8. PubMed PMID: 42119588.

2. Endocrine Society. Polyendocrine Metabolic Ovarian Syndrome: New name to improve diagnosis and care of condition affecting 170 million women worldwide [Internet]. Washington DC: Endocrine Society; 2026 [cited 2026 May 18]. Available from: https://www.endocrine.org/news-and-advocacy/news-room/2026/pcos-name-change

3. Dong J, Rees DA. Polycystic ovary syndrome: Pathophysiology and therapeutic opportunities. BMJ Medicine. 2023;2(1). doi:10.1136/bmjmed-2023-000548.

4. Purwar A, Nagpure S. Insulin resistance in polycystic ovarian syndrome. Cureus. 2022 Oct 16;14(10):e30351. doi:10.7759/cureus.30351.

5. Rojas J, Chavez M, Olivar L, Rojas M, Morillo J, Mejias J, et al. Polycystic Ovary Syndrome, Insulin Resistance, and Obesity: Navigating the Pathophysiologic Labyrinth. Int J Reprod Med. 2014;2014:719050. doi:10.1155/2014/719050.

6. Amisi CA. Markers of insulin resistance in Polycystic ovary syndrome women: An update. World J Diabetes. 2022 Mar 15;13(3):129-49. doi:10.4239/wjd.v13.i3.129.

7. Baptiste CG, Battista MC, Trottier A, Baillargeon JP. Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol. 2010 Oct;122(1-3):42-52. doi:10.1016/j.jsbmb.2009.12.010.

8. Chen X, Wan Y, Xie L. Insulin Resistance in PCOS: Pathophysiological Mechanisms of Menstrual Dysfunction and Evidence-Based Treatment Strategies. Biol Reprod. 2025;ioaf197. doi:10.1093/biolre/ioaf197.

9. Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023;108(10):2447-69. doi:10.1210/clinem/dgad463.

10. Livadas S, Anagnostis P, Bosdou JK, Bantouna D, Paparodis R. Polycystic ovary syndrome and type 2 diabetes mellitus: A state-of-the-art review. World J Diabetes. 2022 Jan 15;13(1):5-26. doi:10.4239/wjd.v13.i1.5.

11. Gambineri A, Patton L, Altieri P, Pagotto U, Pizzi C, Manzoli L, et al. Polycystic Ovary Syndrome Is a Risk Factor for Type 2 Diabetes: Results From a Long-Term Prospective Study. Diabetes. 2012 Sep;61(9):2369-74. doi:10.2337/db11-1360.

12. Chau Thien Tay, Mousa A, Vyas A, Loyal Pattuwage, Fahimeh Ramezani Tehrani, Teede H. 2023 International Evidence-Based Polycystic Ovary Syndrome Guideline Update: Insights From a Systematic Review and Meta-Analysis on Elevated Clinical Cardiovascular Disease in Polycystic Ovary Syndrome. J Am Heart Assoc. 2024 Aug 9;13(16). doi:10.1161/JAHA.123.032720.

13. Ollila MM, Arffman RK, Korhonen E, Morin-Papunen L, Franks S, Junttila MJ, et al. Women with PCOS have an increased risk for cardiovascular disease regardless of diagnostic criteria: a prospective population-based cohort study. Eur J Endocrinol. 2023 Jul 12;189(1). doi:10.1093/ejendo/lvad090.

14. Scicchitano P, Dentamaro I, Carbonara R, Bulzis G, Dachille A, Caputo P, et al. Cardiovascular Risk in Women With PCOS. Int J Endocrinol Metab. 2012 Sep 30;10(4):611-8. doi:10.5812/ijem.4508.

15. Guan C, Zahid S, Minhas AS, Ouyang P, Vaught A, Baker VL, et al. Polycystic ovary syndrome: a “risk-enhancing” factor for cardiovascular disease. Fertil Steril. 2022 May 1;117(5):924-35. doi:10.1016/j.fertnstert.2022.02.014.

16. Kumarendran B, O’Reilly MW, Manolopoulos KN, Toulis KA, Gokhale KM, Sitch AJ, et al. Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: A longitudinal study based on a United Kingdom primary care database. PLoS Med. 2018 Mar 28;15(3):e1002542. doi:10.1371/journal.pmed.1002542.

17. Henney AE, Gillespie CS, Lai JYM, Schofield P, Riley DR, Caleyachetty R, et al. Risk of Type 2 Diabetes, MASLD and Cardiovascular Disease in People Living With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2024 Jul 11. doi:10.1210/clinem/dgae425.

18. Gluszak O, Stopinska-Gluszak U, Glinicki P, Kapuscinska R, Snochowska H, Zgliczynski W, et al. Phenotype and Metabolic Disorders in Polycystic Ovary Syndrome. ISRN Endocrinology. 2012;2012:537271. doi:10.5402/2012/537271.

19. Krentowska A, Kowalska I. Metabolic syndrome and its components in different phenotypes of polycystic ovary syndrome. Diabetes Metab Res Rev. 2021 May 14;37(6):e3446. doi:10.1002/dmrr.3446.

20. Ma YC, Law KS, Wang WS, Chang HM. Phenotypic variations in polycystic ovary syndrome: metabolic risks and emerging biomarkers. J Endocrinol. 2025 Sep 19;267(1). doi:10.1530/JOE-25-0167.

21. Gautam R, Maan P, Jyoti A, Kumar A, Malhotra N, Arora T. The Role of Lifestyle Interventions in PCOS Management: A Systematic Review. Nutrients. 2025 Jan 16;17(2):310. doi:10.3390/nu17020310.

22. Kim CH, Lee SH. Effectiveness of Lifestyle Modification in Polycystic Ovary Syndrome Patients with Obesity: A Systematic Review and Meta-Analysis. Life. 2022 Feb 18;12(2):308. doi:10.3390/life12020308.

23. Wang F, Yan Y, Wang D, Fan Q, Yi F, Yang X, et al. Effects of Metformin on CIMT and FMD in PCOS patients: a systematic review and meta-analysis. BMC Womens Health. 2024 Jul 26;24(1):417. doi:10.1186/s12905-024-03235-0.

24. Palomba S, Falbo A, Russo T, Rivoli L, Orio M, Cosco AG, et al. The Risk of a Persistent Glucose Metabolism Impairment After Gestational Diabetes Mellitus Is Increased in Patients With Polycystic Ovary Syndrome. Diabetes Care. 2012 Feb 14;35(4):861-7. doi:10.2337/dc11-2088.

25. Prosperi S, Chiarelli F. Insulin resistance, metabolic syndrome and polycystic ovaries: an intriguing conundrum. Front Endocrinol. 2025 Oct 1;16:1669716. doi:10.3389/fendo.2025.1669716.

26. Ding H, Zhang J, Zhang F, Zhang S, Chen X, Liang W, et al. Resistance to the Insulin and Elevated Level of Androgen: A Major Cause of Polycystic Ovary Syndrome. Front Endocrinol. 2021 Oct 20;12:741764. doi:10.3389/fendo.2021.741764.

27. Geraci G, Riccio C, Oliva F, Gabrielli D, Colivicchi F, Grimaldi M, et al. Women with PCOS have a heightened risk of cardiometabolic and cardiovascular diseases: statement from the Experts Group on Inositol in Basic and Clinical Research and PCOS (EGOI-PCOS) and Italian Association of Hospital Cardiologists (ANMCO). Front Cardiovasc Med. 2025 Sep 2;12. doi:10.3389/fcvm.2025.1548332.

28. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and Predictors of Risk for Type 2 Diabetes Mellitus and Impaired Glucose Tolerance in Polycystic Ovary Syndrome: A Prospective, Controlled Study in 254 Affected Women. J Clin Endocrinol Metab. 1999 Jan;84(1):165-9. doi:10.1210/jcem.84.1.5393.

29. Badejogbin OC, Agunloye MO, Chijioke-Agu OE, Olubiyi MV, Olugbuyiro SO, Soetan OA, et al. Cardiovascular Dysfunction in Polycystic Ovary Syndrome: Mitochondrial and Inflammatory Mechanisms. BioMed Res Int. 2026;2026(1). doi:10.1155/bmri/5585765.

30. Dobbie LJ, Pittam B, Zhao SS, Alam U, Hydes TJ, Barber TM, et al. Childhood, adolescent, and adulthood adiposity are associated with risk of PCOS: a Mendelian randomization study with meta-analysis. Hum Reprod. 2023 Apr 4;38(4):683-93. doi:10.1093/humrep/dead027.

Why the World Renamed PCOS and What It Means for Women